Treatment of lower risk myelodysplastic syndromes

被引：0

作者：

Park, Sophie ^{[1
]}

机构：

[1] CHU Grenoble, Serv Hematol, CS 10217, F-38043 Grenoble 09, France

来源：

BULLETIN DU CANCER | 2023年 / 110卷 / 11期

关键词：

MDS; ESA; Luspatercept; Lenalidomide; TPO agonists; 5Q DELETION; STIMULATING AGENTS; GROWTH-FACTORS; EPOETIN-ALPHA; MDS; LENALIDOMIDE; PLACEBO; EFFICACY; ANEMIA; DEFERASIROX;

D O I：

10.1016/j.bulcan.2023.02.027

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

For low-risk myelodysplastic syndromes, the goal of treatment is to correct cytopenias or their consequences. Erythropoiesis-stimulating agents have an important role in the management of anemia. In this chapter, we will detail the response to ESAs, the factors predictive of response to ESAs. However, the search for new therapeutic options for low-risk, ESA-resistant MDS remains necessary as the incidence of AML transformation of the patients is higher. We can retain luspatercept for MDS with excess ring of sideroblasts, lenalidomide, and some molecules currently being tested such as imetelstat or roxedustat. However, the search for new therapeutic options for ESA-resistant low-risk MDS remains necessary. We can use androgenotherapy or TPO agonists in limited access for symptomatic thrombocytopenia.

引用

页码：1156 / 1161

页数：6

共 36 条

[31] Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? [J].

Santini, Valeria ;

Schemenau, Jennifer ;

Levis, Alessandro ;

Balleari, Enrico ;

Sapena, Rosa ;

Ades, Lionel ;

Guerci, Agnes ;

Beyne-Rauzy, Odile ;

Gourin, Marie-Pierre ;

Cheze, Stephane ;

Stamatoullas, Aspasia ;

Sanna, Alessandro ;

Gioia, Daniela ;

Cametti, Gianni ;

Ferrero, Dario ;

Raffoux, Emmanuel ;

Rose, Christian ;

Poloni, Antonella ;

Prebet, Thomas ;

Legros, Laurence ;

Natarajan-Ame, Shanti ;

Fenaux, Pierre ;

Germing, Ulrich ;

Dreyfus, Francois ;

Park, Sophie .

BLOOD, 2013, 122 (13) :2286-2288

[32] The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort [J].

Stahl, Maximilian ;

DeVeaux, Michelle ;

de Witte, Theo ;

Neukirchen, Judith ;

Sekeres, Mikkael A. ;

Brunner, Andrew M. ;

Roboz, Gail J. ;

Steensma, David P. ;

Bhatt, Vijaya R. ;

Platzbecker, Uwe ;

Cluzeau, Thomas ;

Prata, Pedro H. ;

Itzykson, Raphael ;

Fenaux, Pierre ;

Fathi, Amir T. ;

Smith, Alexandra ;

Germing, Ulrich ;

Ritchie, Ellen K. ;

Verma, Vivek ;

Nazha, Aziz ;

Maciejewski, Jaroslaw P. ;

Podoltsev, Nikolai A. ;

Prebet, Thomas ;

Santini, Valeria ;

Gore, Steven D. ;

Komrokji, Rami S. ;

Zeidan, Amer M. .

BLOOD ADVANCES, 2018, 2 (14) :1765-1772

[33] Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study [J].

Steensma, David P. ;

Fenaux, Pierre ;

Van Eygen, Koen ;

Raza, Azra ;

Santini, Valeria ;

Germing, Ulrich ;

Font, Patricia ;

Diez-Campelo, Maria ;

Thepot, Sylvain ;

Vellenga, Edo ;

Patnaik, Mrinal M. ;

Jang, Jun Ho ;

Varsos, Helen ;

Bussolari, Jacqueline ;

Rose, Esther ;

Sherman, Laurie ;

Sun, Libo ;

Wan, Ying ;

Dougherty, Souria ;

Huang, Fei ;

Feller, Faye ;

Rizo, Aleksandra ;

Platzbecker, Uwe .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (01) :48-+

[34] Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality [J].

Takatoku, Masaaki ;

Uchiyama, Takashi ;

Okamoto, Shinichiro ;

Kanakura, Yuzuru ;

Sawada, Kenichi ;

Tomonaga, Masao ;

Nakao, Shinji ;

Nakahata, Tatsutoshi ;

Harada, Mine ;

Murate, Takashi ;

Ozawa, Keiya .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 78 (06) :487-494

[35] A randomized phase II trial of azacitidine plus /- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents [J].

Thepot, Sylvain ;

Ben Abdelali, Raouf ;

Chevret, Sylvie ;

Renneville, Aline ;

Beyne-Rauzy, Odile ;

Prebet, Thomas ;

Park, Sophie ;

Stamatoullas, Aspasia ;

Guerci-Bresler, Agnes ;

Cheze, Stephane ;

Tertian, Gerard ;

Choufi, Bachra ;

Legros, Laurence ;

Bastie, Jean Noel ;

Delaunay, Jacques ;

Chaury, Marie Pierre ;

Sanhes, Laurence ;

Wattel, Eric ;

Dreyfus, Francois ;

Vey, Norbert ;

Chermat, Fatiha ;

Preudhomme, Claude ;

Fenaux, Pierre ;

Gardin, Claude .

HAEMATOLOGICA, 2016, 101 (08) :918-925

[36] Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion [J].

Toma, A. ;

Kosmider, O. ;

Chevret, S. ;

Delaunay, J. ;

Stamatoullas, A. ;

Rose, C. ;

Beyne-Rauzy, O. ;

Banos, A. ;

Guerci-Bresler, A. ;

Wickenhauser, S. ;

Caillot, D. ;

Laribi, K. ;

De Renzis, B. ;

Bordessoule, D. ;

Gardin, C. ;

Slama, B. ;

Sanhes, L. ;

Gruson, B. ;

Cony-Makhoul, P. ;

Chouffi, B. ;

Salanoubat, C. ;

Benramdane, R. ;

Legros, L. ;

Wattel, E. ;

Tertian, G. ;

Bouabdallah, K. ;

Guilhot, F. ;

Taksin, A. L. ;

Cheze, S. ;

Maloum, K. ;

Nimuboma, S. ;

Soussain, C. ;

Isnard, F. ;

Gyan, E. ;

Petit, R. ;

Lejeune, J. ;

Sardnal, V. ;

Renneville, A. ;

Preudhomme, C. ;

Fontenay, M. ;

Fenaux, P. ;

Dreyfus, F. .

LEUKEMIA, 2016, 30 (04) :897-905

← 1 2 3 4 →